Mannkind, Game-Chancer in Sachen Diabetik? (Seite 349)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 08.05.24 23:29:18 von
neuester Beitrag 08.05.24 23:29:18 von
Beiträge: 6.835
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 84
Gesamt: 594.251
Gesamt: 594.251
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,3100
USD
-2,05 %
-0,0900 USD
Letzter Kurs 22:30:00 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,2000 | +93,94 | |
| 1,0300 | +37,44 | |
| 1,3300 | +30,51 | |
| 1,9950 | +27,48 | |
| 21,010 | +26,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4650 | -27,50 | |
| 2,2900 | -28,88 | |
| 4,6600 | -41,60 | |
| 2,0200 | -51,79 | |
| 6,5000 | -55,66 |
Beitrag zu dieser Diskussion schreiben
Feedback
Genau und hier ausgeschrieben:
Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs
GlobeNewswire•August 1, 2016
VALENCIA, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) (MNKD) announced it is now distributing MannKind-branded Afrezza® (insulin human) Inhalation Powder directly to major wholesalers and that Afrezza is available by prescription from retail pharmacies nationwide. The MannKind-branded product is associated with new National Drug Code (NDC) numbers, as noted in the table below. With distribution channels now stocked, the Company announced several key programs to promote access, adoption and adherence to Afrezza therapy.
MannKind leveraged nearly two years of experience regarding patient selection and payor access, as well as new clinical data and a better understanding of how patients in the real world manage their titration, to guide its relaunch plans for Afrezza. These plans include the following programs to enhance education and uptake of Afrezza:
A new 30-day titration pack combining 90 4-unit cartridges and 90 8-unit cartridges, allowing patients greater flexibility to adjust their dose as they learn how to titrate Afrezza.
MannKind Cares, a patient reimbursement support program.
A new and enhanced copay assistance program.
Creation of an opportunity for physician offices to purchase in-office spirometers, allowing them to perform pulmonary function testing during the patient visit.
A speakers bureau to educate healthcare providers about Afrezza.
“Relaunching Afrezza as a MannKind brand is one of the most significant milestones in our company’s history,” said Matthew Pfeffer, Chief Executive Officer of MannKind. “We are encouraged by the overwhelmingly positive response we have received from patients, physicians and advocates, who have provided us with tremendous feedback on our relaunch of Afrezza, and whose inputs directly influenced some of the programs announced today.”
While Afrezza is currently covered by commercial payers representing 70% of covered lives, many health plans still require a prior authorization. The MannKind Cares program will streamline the patient and provider experience around the prior authorization process, usually enabling patients to start on Afrezza within days, and enroll patients into a customized adherence program. This program will be available to physicians’ offices beginning the week of August 8th.
MannKind also launched a new and improved copay assistance program, which will reduce the out-of-pocket cost to patients to as little as $15 per month for commercially insured patients. With out-of-pocket costs continuing to be shifted to patients, these programs are important to help patients stay on their treatment plans. The new copay card can be accessed on the Afrezza website, www. Afrezza.com. Prior copay cards activated with Sanofi will continue to be honored and accepted by MannKind.
“Afrezza is a key therapy in the paradigm shift for insulin treatment, but with any major change in healthcare comes a need for education and support services that increase patient and physician awareness,” added Michael Castagna, Chief Commercial Officer of MannKind. “In addition to assembling a best-in-class salesforce with deep device and diabetes experience, our new programs will help streamline and enhance the patient and provider experience with Afrezza. The national sales force began calling on targeted segments across the United States and Puerto Rico in early July.”
In conjunction with launching the commercialization structure and programs, MannKind also announced the appointment of Frank Pompilio, PharmD, as Vice President, of North America Medical Affairs reporting to Chief Medical Officer, Dr. Raymond Urbanski. Dr. Pompilio has over 20 years of experience in healthcare, pharmaceutical, and biotechnology industries. His most current position was Senior Director, Medical Communications at Allergan PLC, where he was responsible for the North American Medical Information call center. Prior to the acquisition of Kythera Biopharmaceuticals by Allergan in 2015, Dr. Pompilio was responsible for the development of the Medical Communications and Medical Information functions at Kythera. Before Kythera, he served as Scientific Affairs Director and Inflammation Medical Communications Therapeutic Area Lead at Amgen Inc. and led a team focused on the synthesis and communication of clinical and scientific data in a balanced and ethical manner to engage and educate the healthcare community with the goal of optimizing patient care.
"Frank is an integral addition to our Clinical Development and Medical Affairs team as we continue to build medical affairs capabilities and infrastructure,” said Dr. Raymond Urbanski. “He has immediate responsibility for MannKind’s medical science liaisons, reaching out to key opinion leaders, managing our medical information platform, and developing and executing our Afrezza medical affairs strategy. I am excited to have Frank’s extensive industry experience at MannKind.”
Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs
GlobeNewswire•August 1, 2016
VALENCIA, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) (MNKD) announced it is now distributing MannKind-branded Afrezza® (insulin human) Inhalation Powder directly to major wholesalers and that Afrezza is available by prescription from retail pharmacies nationwide. The MannKind-branded product is associated with new National Drug Code (NDC) numbers, as noted in the table below. With distribution channels now stocked, the Company announced several key programs to promote access, adoption and adherence to Afrezza therapy.
MannKind leveraged nearly two years of experience regarding patient selection and payor access, as well as new clinical data and a better understanding of how patients in the real world manage their titration, to guide its relaunch plans for Afrezza. These plans include the following programs to enhance education and uptake of Afrezza:
A new 30-day titration pack combining 90 4-unit cartridges and 90 8-unit cartridges, allowing patients greater flexibility to adjust their dose as they learn how to titrate Afrezza.
MannKind Cares, a patient reimbursement support program.
A new and enhanced copay assistance program.
Creation of an opportunity for physician offices to purchase in-office spirometers, allowing them to perform pulmonary function testing during the patient visit.
A speakers bureau to educate healthcare providers about Afrezza.
“Relaunching Afrezza as a MannKind brand is one of the most significant milestones in our company’s history,” said Matthew Pfeffer, Chief Executive Officer of MannKind. “We are encouraged by the overwhelmingly positive response we have received from patients, physicians and advocates, who have provided us with tremendous feedback on our relaunch of Afrezza, and whose inputs directly influenced some of the programs announced today.”
While Afrezza is currently covered by commercial payers representing 70% of covered lives, many health plans still require a prior authorization. The MannKind Cares program will streamline the patient and provider experience around the prior authorization process, usually enabling patients to start on Afrezza within days, and enroll patients into a customized adherence program. This program will be available to physicians’ offices beginning the week of August 8th.
MannKind also launched a new and improved copay assistance program, which will reduce the out-of-pocket cost to patients to as little as $15 per month for commercially insured patients. With out-of-pocket costs continuing to be shifted to patients, these programs are important to help patients stay on their treatment plans. The new copay card can be accessed on the Afrezza website, www. Afrezza.com. Prior copay cards activated with Sanofi will continue to be honored and accepted by MannKind.
“Afrezza is a key therapy in the paradigm shift for insulin treatment, but with any major change in healthcare comes a need for education and support services that increase patient and physician awareness,” added Michael Castagna, Chief Commercial Officer of MannKind. “In addition to assembling a best-in-class salesforce with deep device and diabetes experience, our new programs will help streamline and enhance the patient and provider experience with Afrezza. The national sales force began calling on targeted segments across the United States and Puerto Rico in early July.”
In conjunction with launching the commercialization structure and programs, MannKind also announced the appointment of Frank Pompilio, PharmD, as Vice President, of North America Medical Affairs reporting to Chief Medical Officer, Dr. Raymond Urbanski. Dr. Pompilio has over 20 years of experience in healthcare, pharmaceutical, and biotechnology industries. His most current position was Senior Director, Medical Communications at Allergan PLC, where he was responsible for the North American Medical Information call center. Prior to the acquisition of Kythera Biopharmaceuticals by Allergan in 2015, Dr. Pompilio was responsible for the development of the Medical Communications and Medical Information functions at Kythera. Before Kythera, he served as Scientific Affairs Director and Inflammation Medical Communications Therapeutic Area Lead at Amgen Inc. and led a team focused on the synthesis and communication of clinical and scientific data in a balanced and ethical manner to engage and educate the healthcare community with the goal of optimizing patient care.
"Frank is an integral addition to our Clinical Development and Medical Affairs team as we continue to build medical affairs capabilities and infrastructure,” said Dr. Raymond Urbanski. “He has immediate responsibility for MannKind’s medical science liaisons, reaching out to key opinion leaders, managing our medical information platform, and developing and executing our Afrezza medical affairs strategy. I am excited to have Frank’s extensive industry experience at MannKind.”
Jetzt übernimmt MannKind den Vertrieb von Afrezza offiziell selber:
http://www.nasdaq.com/press-release/mannkind-assumes-respons…
http://www.nasdaq.com/press-release/mannkind-assumes-respons…
Mike erforscht Optionen zum Afrezza Ver/Gebrauch in Mexico:
https://twitter.com/castagna2011/status/748967740568903680
Mexico wäre ein riesen Markt, viele Diabetiker und viele fette Leute, Typ Diabetik II!
https://twitter.com/castagna2011/status/748967740568903680
Mexico wäre ein riesen Markt, viele Diabetiker und viele fette Leute, Typ Diabetik II!
Mike erforscht Optionen zum Afrezza Ver/Gebrauch in Mexico:
[urlEstamos explorando opciones en Mexico! Gracias por tu mensaje!][/url]
Mexico wäre ein riesen Markt, viele Diabetiker und viele fette Leute, Typ Diabetik II!
[urlEstamos explorando opciones en Mexico! Gracias por tu mensaje!][/url]
Mexico wäre ein riesen Markt, viele Diabetiker und viele fette Leute, Typ Diabetik II!
Trading Spotlight
Genau, jetzt werden wir sehen ob SanDofi Afrezza an der ausgetreckten Hand verhungern lassen hat oder ob sich Afrezza nicht besser verkaufen läßt, hopp oder topp!
ab wann sind die 70 Mann exklusiv unterwegs für Mannkind/ Afrezza?
ab dieser Woche? das sollte sich- hoffentlich- positiv niederschlagen. Jetzt gilt es.
ab dieser Woche? das sollte sich- hoffentlich- positiv niederschlagen. Jetzt gilt es.
jetzt wird wie bei allen Bios wieder Luft abgelassen
Kennt Ihr Outsulin schon? Und soll der Computer für den Relaunch neu gestartet werden?
https://twitter.com/castagna2011
https://twitter.com/castagna2011
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
